Lori Lyons-Williams Joins Dermira as Chief Commercial Officer
January 05, 2017 07:30 ET
|
Dermira, Inc.
Previously served at Allergan as a Vice President for Sales & Marketing, member of Operational Leadership TeamWorked on several leading dermatology brands including ACZONE® and BOTOX® during...
Dermira Elects Emmanuel Caeymaex to Board of Directors
January 04, 2017 16:05 ET
|
Dermira, Inc.
MENLO PARK, Calif., Jan. 04, 2017 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ:DERM), a biopharmaceutical company dedicated to identifying, developing and commercializing innovative, differentiated...
Dermira Initiates Phase 3 Clinical Program in Acne
January 03, 2017 07:30 ET
|
Dermira, Inc.
First patients dosed in Phase 3 program evaluating olumacostat glasaretil, a novel topical molecule, in patients with acne vulgarisTwo Phase 3 trials expected to enroll a total of 1,400...
Second CIMZIA® (certolizumab pegol) Phase 3 Trial Meets Co-primary Efficacy Endpoints in Patients with Moderate-to-Severe Chronic Plaque Psoriasis
December 08, 2016 02:00 ET
|
Dermira, Inc.
Topline results from CIMPASI-1, the second of three Phase 3 trials in psoriasis clinical development programFindings confirm CIMZIA results observed in earlier CIMPASI-2 trialResults from third and...
Dermira to Present at Stifel 2016 Healthcare Conference
November 09, 2016 16:05 ET
|
Dermira, Inc.
MENLO PARK, Calif., Nov. 09, 2016 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ:DERM), a biopharmaceutical company dedicated to identifying, developing and commercializing innovative, differentiated...
Dermira Reports Third Quarter 2016 Financial Results and Provides Corporate Update
November 07, 2016 16:07 ET
|
Dermira, Inc.
- Topline results for the first of three Phase 3 trials for CIMZIA® reported - DRM04 Phase 3 and DRM01 Phase 2b data presented at dermatology conferences - Acquired option to...
Dermira Presents Data from DRM01 Phase 2b Clinical Program at Annual Meeting for Dermatologists
October 21, 2016 07:30 ET
|
Dermira, Inc.
MENLO PARK, Calif., Oct. 21, 2016 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ:DERM), a biopharmaceutical company dedicated to identifying, developing and commercializing innovative, differentiated...
Dermira to Present Data from DRM01 and DRM04 Clinical Programs at Fall Clinical Dermatology Conference
October 13, 2016 07:30 ET
|
Dermira, Inc.
MENLO PARK, Calif., Oct. 13, 2016 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ:DERM), a biopharmaceutical company dedicated to identifying, developing and commercializing innovative, differentiated...
CIMZIA® (certolizumab pegol) Phase 3 Trial Meets Co-primary Efficacy Endpoints in Patients with Moderate-to-Severe Chronic Plaque Psoriasis
October 03, 2016 02:00 ET
|
Dermira, Inc.
BRUSSELS, Belgium and MENLO PARK, Calif., Oct. 03, 2016 (GLOBE NEWSWIRE) -- UCB (Euronext:UCB) and Dermira, Inc. (NASDAQ:DERM) today announced topline results from CIMPASI-2, a Phase 3,...
Dermira to Present Data from DRM04 Phase 3 Clinical Trials at Late-Breaking News Session at European Academy of Dermatology and Venereology Congress
September 28, 2016 07:30 ET
|
Dermira, Inc.
MENLO PARK, Calif., Sept. 28, 2016 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ:DERM), a biopharmaceutical company dedicated to identifying, developing and commercializing innovative, differentiated...